Form: 8-K

Current report

November 16, 2026

0001595097false00015950972026-11-162026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37348

46-4348039

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

500 River Ridge Drive

Norwood, Massachusetts

02062

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CRBP

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 

Item 7.01 Regulation FD Disclosure.

On November 16, 2026, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release announcing that additional data from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity were presented in a poster at ObesityWeek® 2026 (The International Meeting Advancing Obesity Science and Patient Care), held November 14–17, 2026 in Washington, D.C. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 8.01 Other Events.

 

On November 16, 2026, the Company announced that additional data from the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity were presented in a poster at ObesityWeek® 2026. The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of 5% at 12 weeks. CRB-913 had a favorable safety and tolerability profile. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is line with published GLP-1 data. Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe treatment-emergent psychiatric AEs were reported. These data support CRB-913’s potential to establish a new class of oral, non-incretin obesity medicines.

Study Design

The CANYON-1 Phase 1b clinical trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). A dose titration regimen was used, with all participants receiving CRB-913 starting at 20 mg/day and those assigned to the higher-dose cohorts titrating up every two weeks to either 40 mg/day or 60 mg/day, depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.

Efficacy

CRB-913 demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses. Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort.


 

 

CRB-913

Cohort

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

LS mean weight loss from baseline at week 12, %1

0.0%

2.8%

3.3%

5.0%

LS mean weight loss at week 12, % (placebo-adjusted)1

NA

2.8%

3.3%

5.0%

p-value vs. placebo

NA

<0.0001

<0.0001

<0.0001

Change in waist circumference from baseline, cm

-0.84

-3.03

-3.04

-3.94

p-value

0.21

<0.0001

<0.0001

<0.0001

BMI percent change from baseline

-0.06

-2.81

-3.34

-4.99

p-value

0.89

<0.0001

<0.0001

<0.0001

1 Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.

All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline. Participants treated with CRB-913 also experienced dose-dependent reductions in waist circumference and body mass index during the study.

Safety

CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data.


 

 

CRB-913

 

Safety measure

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Total
(N = 254)

Any TEAE, n (%)

28 (42.4)

39 (60.0)

45 (73.8)

45 (72.6)

157 (61.8)

Severe TEAE

0 (0.0)

3 (4.6)

2 (3.3)

1 (1.6)

6 (2.4)

Severe psychiatric TEAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Severe gastrointestinal TEAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Serious TEAE

0 (0.0)

2 (3.1)

1 (1.6)

1 (1.6)

4 (1.6)

Any TRAE, n (%)

14 (21.2)

27 (41.5)

34 (55.7)

33 (53.2)

108 (42.5)

Severe TRAE

0 (0.0)

0 (0.0)

1 (1.6)

0 (0.0)

1 (0.4)

Serious TRAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Treatment discontinuation for any reason, n (%)

12 (18.2)

10 (15.4)

16 (26.2)

16 (25.8)

54 (21.3)

Treatment discontinuation due to an AE, n (%)

3 (4.5)

2 (3.1)

8 (13.1)

8 (12.9)

21 (8.3)

Psychiatric Adverse Events

Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.

 

 

CRB-913

Adverse event, n (%)

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Suicidality

0

0

0

0

Depressive symptoms

0

0

0

1 (1.6%)
(moderate)

Anxiety

3 (4.5%)

2 (3.1%)

5 (8.2%)

3 (4.8%)

Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (8%) on CRB-913 reported mild irritability that was transient, resolved spontaneously, and did not affect their daily function. All 15 participants experienced weight loss, and 12 participants had concomitant unrelated AEs.


Gastrointestinal Adverse Events

Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.

 

 

CRB-913

Adverse event, n (%)

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Vomiting

0

3 (4.6%)

5 (8.2%)

1 (1.6%)

Nausea

3 (4.5%)

10 (15.4%)

16 (26.2%)

14 (22.6%)

Constipation

2 (3.0%)

3 (4.6%)

1 (1.6%)

3 (4.8%)

Diarrhea

2 (3.0%)

14 (21.5%)

16 (26.2%)

14 (22.6%)

Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).

Next Steps

Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including statements concerning the potential benefits and further development of CRB-913, future clinical studies and regulatory discussions, including with the FDA, and potential combination therapies. These statements reflect the Company’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially, including the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Additional risks are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Forward-looking statements speak only as of the date of this Current Report, and the Company undertakes no obligation to update them except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.

Description

99.1

 

Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 16, 2026.

99.2

 

Investor Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date:

November 16, 2026

By:

/s/ Yuval Cohen

Name: Yuval Cohen
Title: Chief Executive Officer